Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial

Document Type : Original Research Article

Authors

1 Department of Microbiology, Infection and Tropical Diseases Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Emergency Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Department of Infectious Diseases, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Department of Pharmacology and Toxicology Research Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

5 Department of Internal Medicine, School of Medicine, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

6 Nanotechnology Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

7 Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

8 Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

9 Department of Biochemistry, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran

10 Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

11 Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

12 Department of Biochemistry, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran

10.22038/ajp.2024.24523

Abstract

Objective: Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.
Materials and Methods: We assessed effect of shallomin oral syrup (co IranAmin®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.
Results: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.
Conclusion: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.

Keywords

Main Subjects